Related Funds
Funds with similar focus
Fund Name | Location |
3D Systems | Rock Hill, South Carolina, United States |
Caribou Asset Management | - |
Cronus Bike | China, Guangdong Province, Panyu District |
Gamma3 | Brazil, Curitiba, Paraná |
Ibtikar Fund | Area A, Palestinian Territory, West Bank |
Incapital | Chicago, Illinois, United States |
Jinfu Ziben | Beijing, Beijing, China |
Katana Fund | - |
Marlin Equity Partners | California, Hermosa Beach, United States |
Montlake Capital | Seattle, United States, Washington |
Oman Investment Fund | Masqat, Muscat, Oman |
Power Generations, Inc. | Florida, Pompano Beach, United States |
Redfig | - |
Shoei Chemical | - |
Transmedia Ventures | California, San Francisco, United States |
Tricle | Japan, Tokyo |
Verbena Communications | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Zenas BioPharma | $200M | 07 May 2024 | - | ||
Zenas BioPharma | $118M | 07 Nov 2022 | - | ||
Sironax | $200M | 02 Aug 2022 | Dongcheng District, Beijing, China | ||
Shoreline Biosciences | $140M | 02 Nov 2021 | San Diego, California, United States | ||
ReCode Therapeutics | $80M | 21 Oct 2021 | Dallas, Texas, United States | ||
dMed | $50M | 10 Jul 2021 | Shanghai, China | ||
Clinipace | $50M | 08 Jul 2021 | North Carolina, United States | ||
$105M | 13 May 2021 | Shanghai, China | |||
AffaMed Therapeutics | $170M | 30 Mar 2021 | New York, United States |
– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Zenas BioPharma | $200M | 07 May 2024 | - | ||
Zenas BioPharma | $118M | 07 Nov 2022 | - | ||
Sironax | $200M | 02 Aug 2022 | Dongcheng District, Beijing, China | ||
Shoreline Biosciences | $140M | 02 Nov 2021 | San Diego, California, United States | ||
ReCode Therapeutics | $80M | 21 Oct 2021 | Dallas, Texas, United States | ||
dMed | $50M | 10 Jul 2021 | Shanghai, China | ||
Clinipace | $50M | 08 Jul 2021 | North Carolina, United States | ||
$105M | 13 May 2021 | Shanghai, China | |||
AffaMed Therapeutics | $170M | 30 Mar 2021 | New York, United States |